Advertisement
Research Article Free access | 10.1172/JCI110320
Find articles by Tolis, G. in: JCI | PubMed | Google Scholar
Find articles by Mehta, A. in: JCI | PubMed | Google Scholar
Find articles by Comaru-Schally, A. in: JCI | PubMed | Google Scholar
Find articles by Schally, A. in: JCI | PubMed | Google Scholar
Published September 1, 1981 - More info
Four male transsexual subjects were given a superactive luteinizing hormone-releasing hormone (LHRH) analogue, D-tryptophan-6-LHRH at daily doses of 100 micrograms for 3--6 mo. A decrease in beard growth, acne, and erectile potency was noted; the latter was documented objectively with the recordings of nocturnal penile tumescence episodes. Plasma testosterone and dihydrotestosterone levels fell to castrate values; basal prolactin and luteinizing hormone levels showed a small decline, whereas the acutely releasable luteinizing hormone was significantly suppressed. A rise of plasma testosterone from castrate to normal levels was demonstrable with the use of human chorionic gonadotropin. Discontinuation of treatment led to a normalization of erectile potency and plasma testosterone. The suppression of Leydig cell function by D-tryptophan-6-LHRH might have wide application in reproductive biology and in endocrine-dependent neoplasia (where it could replace surgical castration).
Click on an image below to see the page. View PDF of the complete article